AstraZeneca PLC (LON:AZN) Receives £117.13 Average Target Price from Analysts

AstraZeneca PLC (LON:AZNGet Free Report) has earned a consensus rating of “Hold” from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is £115.43 ($146.09).

Several research analysts have commented on AZN shares. UBS Group dropped their price objective on shares of AstraZeneca from £107 ($135.43) to GBX 9,900 ($125.30) and set a “sell” rating for the company in a research note on Monday, February 12th. Barclays reaffirmed an “overweight” rating and set a £125 ($158.21) price objective on shares of AstraZeneca in a research note on Monday. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of AstraZeneca in a research note on Tuesday, March 12th. Shore Capital restated a “buy” rating on shares of AstraZeneca in a report on Friday, April 5th. Finally, BMO Capital Markets restated an “outperform” rating on shares of AstraZeneca in a report on Monday, February 12th.

Read Our Latest Stock Analysis on AstraZeneca

AstraZeneca Stock Up 1.6 %

LON AZN opened at £111.40 ($140.99) on Friday. The company has a quick ratio of 0.59, a current ratio of 0.82 and a debt-to-equity ratio of 75.70. The company has a fifty day moving average of £103.08 and a two-hundred day moving average of £104.35. The firm has a market capitalization of £172.67 billion, a price-to-earnings ratio of 3,629.80, a PEG ratio of 0.87 and a beta of 0.17. AstraZeneca has a 52 week low of GBX 9,461 ($119.74) and a 52 week high of £123.92 ($156.84).

AstraZeneca Increases Dividend

The firm also recently disclosed a dividend, which was paid on Monday, March 25th. Investors of record on Thursday, February 22nd were paid a GBX 156 ($1.97) dividend. The ex-dividend date of this dividend was Thursday, February 22nd. This is a positive change from AstraZeneca’s previous dividend of $71.80. This represents a yield of 1.49%. AstraZeneca’s dividend payout ratio is 7,549.67%.

AstraZeneca Company Profile

(Get Free Report

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Featured Articles

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.